Marimed (MRMD) Cash from Financing Activities (2014 - 2026)

Marimed (MRMD) has 13 years of Cash from Financing Activities data on file, last reported at -$1.1 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$1.1 million, up 9.21% year-over-year; the trailing twelve-month figure through Mar 2026 was -$4.6 million (down 5775.31% YoY), and the FY2025 annual result was -$4.7 million, down 257.89% from the prior year.
• Cash from Financing Activities retreated to -$1.1 million in Q1 2026 per MRMD's latest filing, from -$944000.0 in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $23.3 million in Q1 2023 and troughed at -$3.1 million in Q3 2023.
• A 5-year average of $1.1 million and a median of -$806000.0 in 2025 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities plunged 1349.15% in 2022, then jumped 7176.6% in 2023.
• A 5-year view of Cash from Financing Activities shows it stood at -$600000.0 in 2022, then soared by 850.0% to $4.5 million in 2023, then sank by 119.84% to -$893000.0 in 2024, then declined by 5.71% to -$944000.0 in 2025, then decreased by 21.08% to -$1.1 million in 2026.
• Business Quant data shows MRMD's Cash from Financing Activities at -$1.1 million in Q1 2026, -$944000.0 in Q4 2025, and -$1.7 million in Q3 2025.